Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

ch-toulon.fr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

77

Active

21

Phase 3

3

Total enrollment

26,990

Pipeline matrix

Showing 1 of 1 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Repotrectinib1

Next readouts

  • 2031-09

Top conditions

  • Chronic Obstructive Pulmonary Disease (COPD)3
  • Pulmonary Embolism3
  • Deep Vein Thrombosis2
  • COVID-192
  • Moral Injury2
  • Drug Use2
  • Respiratory Distress Syndrome2
  • Covid-192

Frequently asked questions about Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

How many clinical trials does Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer have on ClinicalTrials.gov?
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
How many of Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's trials are in Phase 3?
3 of Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's trials are in Phase 3, spread across 1 active drug program.
What therapeutic areas does Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer focus on?
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's most-studied conditions on ClinicalTrials.gov are Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Embolism, Deep Vein Thrombosis, COVID-19, Moral Injury.
When are Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's next clinical trial readouts?
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer has 1 upcoming primary-completion readout tracked here; the soonest is “Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC”, expected around 2031-09.